Latest Pig Industry News
Boehringer Ingelheim Offers PRRS Profiling In The New Year
MISSOURI - Boehringer Ingelheim Vetmedica, Inc. (BIVI) is offering swine producers diagnostic profiling services to protect pigs from porcine reproductive and respiratory syndrome (PRRS).
The BIVI diagnostic profiling service can accurately assess the exposure pattern of the PRRS virus and determine if vaccine use can help reduce the economic impact of a PRRS infection in a herd. Large commercial field trials have shown that vaccinating healthy growing pigs can aid in the reduction of PRRS-induced disease during the growing-finishing stage, resulting in increased feed efficiency and average daily gain and reduced mortality.
The use of profiling phases of production and exposure to the PRRS virus can determine if there is a need to vaccinate pigs that may need PRRS protection later in life.
Ingelvac® PRRS ATP and Ingelvac® PRRS MLV aid in the reduction of PRRS-induced disease when administered to healthy, yet susceptible swine four weeks prior to field virus exposure.
Producers wanting to take advantage of the diagnostic profiling services should call Boehringer Ingelheim Vetmedica, Inc. at 800-325-9167. Diagnostic services offer available for a limited time.
Boehringer Ingelheim Vetmedica, Inc. (St. Joseph, Mo.), is a subsidiary of Boehringer Ingelheim Corporation based in Ridgefield, Conn., and a member of the Boehringer Ingelheim group of companies.
The Boehringer Ingelheim group is one of the world’s 20 leading pharmaceutical companies. Headquartered in Ingelheim, Germany, it operates globally with 144 affiliates in 45 countries and nearly 36,000 employees. Since it was founded in 1885, the family-owned company has been committed to researching, developing, manufacturing and marketing novel products of high therapeutic value for human and veterinary medicine.
In 2004, Boehringer Ingelheim posted net sales of US $10.2 billion (8.2 billion euro) while spending nearly one-fifth of net sales in its largest business segment, Prescription Medicines, on research and development.
Source: Boehringer Ingelheim UK - 7th December 2004
More of the latest Pig Industry News
Latest Pig Prices from China
New AI Station Commissioned in Malta
Pork Producers Shy Away from DDGS
LEI Publishes Report on Pig Welfare in Argentina
Organic Acids, Tannins as Alternatives to AGPs
Chinese Pork Market to Reopen to US- Tryptophan-Enriched Diet Reduces Pig Aggression
Agromek Show Turns to Alternate-Year Cycle- CME: Pork, Beef Prices Up; Chicken Prices Steady
Strong CAP Needed to Help Europe Grow
